Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1995 1
1996 2
1998 1
2004 3
2005 4
2006 3
2007 3
2008 2
2009 6
2010 4
2011 8
2012 7
2013 8
2014 9
2015 19
2016 13
2017 7
2018 12
2019 13
2020 16
2021 13
2022 13
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anita greater
Search for Anita Greiter instead (2 results)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Free article. Clinical Trial.
RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage …
RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points great …
Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options.
Desai P, Aggarwal A. Desai P, et al. Clin Geriatr Med. 2021 Nov;37(4):611-623. doi: 10.1016/j.cger.2021.05.007. Epub 2021 Jul 30. Clin Geriatr Med. 2021. PMID: 34600726 Review.
Breast cancer is becoming increasingly prevalent in the women greater than 65 years of age. Most tumors are hormone receptor-positive in this group. ...
Breast cancer is becoming increasingly prevalent in the women greater than 65 years of age. Most tumors are hormone receptor-positive …
Noradrenergic circuit control of non-REM sleep substates.
Osorio-Forero A, Cardis R, Vantomme G, Guillaume-Gentil A, Katsioudi G, Devenoges C, Fernandez LMJ, Lüthi A. Osorio-Forero A, et al. Curr Biol. 2021 Nov 22;31(22):5009-5023.e7. doi: 10.1016/j.cub.2021.09.041. Epub 2021 Oct 13. Curr Biol. 2021. PMID: 34648731 Free article.
These fluctuations occurred around mean noradrenaline levels greater than the ones of quiet wakefulness, while noradrenaline (NA) levels declined steeply in REMS. ...
These fluctuations occurred around mean noradrenaline levels greater than the ones of quiet wakefulness, while noradrenaline (NA) lev …
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Douillard JY, et al. Lancet Oncol. 2006 Sep;7(9):719-27. doi: 10.1016/S1470-2045(06)70804-X. Lancet Oncol. 2006. PMID: 16945766 Clinical Trial.
Tolerance to chemotherapy mainly included neutropenia in 335 (92%) patients and febrile neutropenia in 34 (9%); seven (2%) toxic deaths were also recorded. Compliance was greater with cisplatin than with vinorelbine (median dose intensity 89% [range 17-108] vs 59% [17-100] …
Tolerance to chemotherapy mainly included neutropenia in 335 (92%) patients and febrile neutropenia in 34 (9%); seven (2%) toxic deaths were …
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Blüher M, et al. Diabetologia. 2024 Mar;67(3):470-482. doi: 10.1007/s00125-023-06053-9. Epub 2023 Dec 14. Diabetologia. 2024. PMID: 38095657 Free PMC article. Clinical Trial.
Mean (95% CI) bodyweight decreased dose-dependently up to -8.7% (-10.1, -7.3; DG6, n=37); survodutide 1.8 mg qw produced greater bodyweight reductions than semaglutide (-5.3% [-6.6, -4.1]; n=45). ...
Mean (95% CI) bodyweight decreased dose-dependently up to -8.7% (-10.1, -7.3; DG6, n=37); survodutide 1.8 mg qw produced greater body …
Perspectives in weight control in diabetes - Survodutide.
Klein T, Augustin R, Hennige AM. Klein T, et al. Diabetes Res Clin Pract. 2024 Jan;207:110779. doi: 10.1016/j.diabres.2023.110779. Epub 2023 Jun 15. Diabetes Res Clin Pract. 2024. PMID: 37330144
These data highlight the potential of dual GCGR/GLP-1R agonism for reducing glycated haemoglobin and body weight in patients with Type 2 diabetes mellitus, and for greater therapeutic efficacy compared with GLP-1R agonism alone....
These data highlight the potential of dual GCGR/GLP-1R agonism for reducing glycated haemoglobin and body weight in patients with Type 2 dia …
Tackling obesity in knee osteoarthritis.
Wluka AE, Lombard CB, Cicuttini FM. Wluka AE, et al. Nat Rev Rheumatol. 2013 Apr;9(4):225-35. doi: 10.1038/nrrheum.2012.224. Epub 2012 Dec 18. Nat Rev Rheumatol. 2013. PMID: 23247649 Review.
The degree of weight loss required to achieve benefit might be greater with increasing disease severity. Finally, we outline the need for a societal approach to tackle obesity-related OA....
The degree of weight loss required to achieve benefit might be greater with increasing disease severity. Finally, we outline the need …
Assessment and management of radiotherapy induced toxicity in older patients.
O'Donovan A, Leech M, Gillham C. O'Donovan A, et al. J Geriatr Oncol. 2017 Nov;8(6):421-427. doi: 10.1016/j.jgo.2017.07.001. Epub 2017 Jul 21. J Geriatr Oncol. 2017. PMID: 28739158 Review.
Altered fractionation regimes have been employed in numerous sites, with no significant toxicity impact. These offer greater convenience in the elderly, especially those with limited social support or in active caregiving roles. ...
Altered fractionation regimes have been employed in numerous sites, with no significant toxicity impact. These offer greater convenie …
159 results